Use of staurosporine derivatives for the treatment of multiple Myeloma

Details for Australian Patent Application No. 2005313556 (hide)

Owner The Brigham and Women's Hospital Dana-Farber Cancer Institute, Inc.

Inventors Gilliland, D. Gary; Chen, Jing; Griffin, James Douglas; Anderson, C. Kenneth

Agent Davies Collison Cave

Pub. Number AU-B-2005313556

PCT Pub. Number WO2006/061199

Priority 0426821.5 07.12.04 GB

Filing date 7 December 2005

Wipo publication date 15 June 2006

Acceptance publication date 27 August 2009

International Classifications

A61K 31/407 (2006.01) - condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61P 7/00 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

28 June 2007 PCT application entered the National Phase

  PCT publication WO2006/061199 Priority application(s): WO2006/061199

27 August 2009 Application Accepted

  Published as AU-B-2005313556

24 December 2009 Standard Patent Sealed

30 June 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005313557-Anthranilamide derivatives as insecticides

2005313550-Indenyl derivatives and use thereof for the treatment of neurological disorders